Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are intolerant to platinum chemotherapy or whose disease has progressed.

Scroll to Top